Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Speculation On Baxter Division Picks Up Steam

Executive Summary

The company reported in October that it was reviewing its portfolio and would offer more details on its future plans in January. Wells Fargo analysts expect Baxter to split its fast-growing connected care business from its lower-margin hospital-based therapeutics products.

You may also be interested in...



Medtronic’s Med Surg President Speaks On Development Strategy, Recent Deals And Hopes For Future

Bob White, president of Medtronic’s medical surgical portfolio spoke to Medtech Insight about how the company develops innovative products like the Hugo robot, recent deals that carved out businesses, and the biggest opportunities for future growth and innovation.

J&J Pumps MedTech Growth; Offers $16.6BN+ For Abiomed

Johnson & Johnson plans to buy Abiomed for $380 per share – about $16.6bn in total – plus up to $35 per share in potential commercial and clinical milestone-contingent payments. Abiomed is the clear leader in percutaneous circulatory support technology, but would benefit from J&J's reach and resources while complementing J&J's Biosense Webster electrophysiology business.

Medtronic Cuts Away More: Spins Off Patient Monitoring And Respiratory Business

Medtronic announced plans to spin off its patient monitoring and respiratory interventions businesses, which currently provide revenues of over $2bn a year. The company previously signaled plans to make significant changes to its business portfolio.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT146054

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel